The bloating that showed up in perimenopause felt different from anything before — not just uncomfortable, but somehow wrong, like the body had stopped recognizing food it had handled fine for decades. It took a long time to find anyone who connected it to hormones rather than just handing over a low-FODMAP sheet and calling it IBS. If that story sounds familiar, this one's for you.
Learn more about Rose →The migrating motor complex (MMC) is the gut's housekeeping wave — a pattern of muscular contractions that sweeps bacteria and debris from the small intestine between meals, preventing microbial buildup. Estrogen receptors are present throughout the gastrointestinal tract, and research shows that declining estrogen directly reduces MMC frequency and amplitude. A sluggish MMC allows bacteria to accumulate in the small intestine rather than being pushed into the colon where they belong — a textbook setup for SIBO.
Progesterone is well known for relaxing smooth muscle — it's why constipation is common in pregnancy when progesterone is high. In perimenopause, progesterone levels drop erratically and often fall before estrogen does, removing a regulatory influence on intestinal muscle tone. This contributes to altered motility patterns that can swing between constipation and diarrhea, both of which are associated with disrupted bacterial clearance from the small bowel.
Studies comparing pre- and postmenopausal women show measurable differences in gut microbiome composition, including reductions in Lactobacillus species and shifts in Firmicutes-to-Bacteroidetes ratios. These changes reduce competitive inhibition — the mechanism by which resident bacteria suppress opportunistic species from overproliferating. When the microbial landscape loses diversity and balance, the conditions for small intestinal bacterial overgrowth become more permissive.
Secretory IgA (sIgA) is an antibody produced in the gut lining that helps regulate which microorganisms are tolerated and which are kept in check. Estrogen has been shown to upregulate sIgA production, and postmenopausal women demonstrate lower mucosal sIgA levels compared to premenopausal women. Reduced sIgA means the small intestine is less equipped to prevent bacterial populations from establishing themselves where they shouldn't be.
Estrogen helps maintain the tight junctions between intestinal epithelial cells — the structures that keep gut contents from leaking into the bloodstream. As estrogen falls, intestinal permeability increases, a phenomenon sometimes called leaky gut. SIBO independently worsens this permeability through bacterial metabolite production, creating a reinforcing cycle: hormonal decline opens the door, and SIBO keeps it wedged open.
The HPA axis becomes less well-regulated during perimenopause, leading to higher baseline cortisol and more erratic cortisol patterns throughout the day. Cortisol and other stress hormones are known to suppress the migrating motor complex and slow gastrointestinal transit — independent of estrogen and progesterone effects. This means the gut motility disruption in perimenopause is coming from multiple hormonal directions simultaneously, compounding SIBO risk.
Unlike general dysbiosis, SIBO has a physiological signature: bacteria fermenting carbohydrates in the small intestine produce hydrogen gas, and archaea convert some of that hydrogen into methane. Hydrogen-dominant SIBO tends to correlate with diarrhea-predominant symptoms; methane-dominant SIBO is strongly associated with constipation. This distinction matters because many perimenopausal women describe bloating that appears within 60 to 90 minutes of eating — the timeframe consistent with small intestinal, not colonic, fermentation.
SIBO bacteria produce histamine and other biogenic amines as fermentation byproducts, which can provoke symptoms that look identical to food sensitivities or allergies — flushing, bloating, headache, skin reactions, and digestive distress. Women in perimenopause who suddenly find themselves reacting to wine, aged cheese, fermented foods, or high-histamine items may be responding to SIBO-driven histamine load rather than developing true intolerances. Treating the underlying SIBO often resolves these apparent new sensitivities without permanent dietary restriction.
IBS is a functional diagnosis based on symptom patterns; SIBO is a diagnosable condition of bacterial overgrowth confirmed by breath testing (lactulose or glucose hydrogen/methane breath test). Many women are given an IBS label during perimenopause when SIBO is the underlying driver — and the treatments differ significantly, with SIBO typically requiring targeted antimicrobial therapy (pharmaceutical or herbal) and motility support rather than just dietary management. Pursuing proper testing before committing to long-term restrictive diets is worth raising with a knowledgeable gastroenterologist or functional medicine practitioner.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.